Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

- PMLiVE

Merck KGaA acquires cancer drug from Symphogen

Will pay up to €495m for investigational metastatic colorectal cancer treatment

- PMLiVE

Takeda’s Revestive becomes first approved drug in Europe for short bowel syndrome

Can reduce dependency on intravenous feeding

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

- PMLiVE

Pharma deals during August 2012

In this regular review of deals we focus on transactions announced during August 2012

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

Valeant offers $2.6bn to buy dermatology firm Medicis

Possible further addition to long list of Canadian pharma firm’s acquisitions

- PMLiVE

COPD needs to learn risk reductions lessons from heart disease

Takeda-backed report says HCPs working in COPD need to learn from progress made by their colleagues in cardiovascular medicine

Bristol-Myers Squibb (BMS) building

BMS halts hep C candidate development after patient death

Promises to share drug data to assist other pharma companies’ patient safety measures

Allergan signs $1.4bn eye drug deal with Molecular Partners

Will develop DARPin proteins to target AMD and other eye conditions

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links